Is CURIS INC (CRIS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 21.7% / 30% | 147.1% / 30% | 24.6% / 30% | 16.21% / 5% | ✗ NOT HALAL |
| DJIM | 21.7% / 33% | 147.1% / 33% | 24.6% / 33% | 16.21% / 5% | ✗ NOT HALAL |
| MSCI | 7.2% / 33% | 48.5% / 33% | 8.1% / 33% | 16.21% / 5% | ✗ NOT HALAL |
| S&P | 21.7% / 33% | 147.1% / 33% | 24.6% / 33% | 16.21% / 5% | ✗ NOT HALAL |
| FTSE | 7.2% / 33% | 48.5% / 33% | 8.1% / 50% | 16.21% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -199.7% | |
| Operating Margin | -665.2% | |
| Net Margin | -80.3% | |
| Return on Assets (ROA) | -67.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$40M |
| Free Cash Flow | -$40M |
| Total Debt | $3M |
| Debt-to-Equity | 29.6 |
| Current Ratio | 0.5 |
| Total Assets | $41M |
Price & Trading
| Last Close | $0.58 |
| 50-Day MA | $0.95 |
| 200-Day MA | $1.42 |
| Avg Volume | 519K |
| Beta | 3.0 |
|
52-Week Range
$0.52
| |
About CURIS INC (CRIS)
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CURIS INC (CRIS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CURIS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CURIS INC's debt ratio?
CURIS INC's debt ratio is 21.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.2%.
What are CURIS INC's key financial metrics?
CURIS INC has a market capitalization of $22M, and revenue of $11M. The company maintains a gross margin of -199.7% and a net margin of -80.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.